The countdown timer on the VitalSync terminal reached 00:00:00 at 6:13 AM.
Eleanor Vance did not die.
Silas watched as the red alert banner flickered, dissolved, and was replaced by a calm green display: RISK NORMALIZED. TIME TO NEXT ASSESSMENT: 24H 00M. The old woman in the bed stirred, opened her eyes, and asked for water. Her voice was weak but steady. Her heart rate was 74. Her blood pressure was 134/80. She was, by all measurable parameters, stable.
Dr. Lena Cordova arrived at 6:30 AM, her tablet in hand, her expression carefully neutral. She examined the terminal, checked Mrs. Vance's vitals manually, and made a note in the patient's chart. "The system predicted a high-risk event," she said, as if reciting from a script. "Intervention was administered. The prediction was averted. This is exactly how VitalSync is designed to function."
Silas, exhausted and stiff from a night in a plastic chair, studied her face for any sign of relief, surprise, or disappointment. He found none. She was a closed door. "You said the predictions were remarkably accurate," he said. "Ninety-four percent, according to OmniCure's marketing materials. A false positive of this magnitude should be statistically notable."
"Medicine is not pure mathematics, Professor Crane. Patients are complex systems. The algorithm accounts for variables that even I don't fully understand."
"That is precisely my concern."
Dr. Cordova's lips tightened. "Mrs. Vance is alive. That is the outcome that matters. I suggest you get some rest. You look terrible."
She left. Silas remained in the chair for another ten minutes, watching the VitalSync screen cycle through its green-tinted reassurances. The old woman had fallen back asleep, her breathing deep and regular. A reprieve. But Silas could not shake the feeling that he had witnessed not a prediction but a performance. A demonstration. Someone, somewhere, had known he was watching.
He returned to Room 104 at 7:00 AM and found Lila Vance sitting in the vinyl armchair, her posture rigid, her eyes red-rimmed from a sleepless night. On the bedside table, next to his blue notebook, lay a white business card embossed with a silver double helix.
"Asterion Equity Partners," Lila said before he could ask. "A man named Kellan Drue visited my motel room at midnight. He knew my real name, my former rank, my pension details, and the fact that I had called Arthur Cho. He suggested, with exquisite politeness, that I discontinue my interest in OmniCure. When I declined, he implied that my pension might be vulnerable to a sudden audit."
Silas picked up the business card. The paper was heavy, expensive. The logo was a stylized helix intertwined with a dollar sign. "They are watching us."
"They are watching you," Lila corrected. "I am a new variable. They have been watching you since the moment you photographed Harold Finch's terminal. The question is why they haven't acted more aggressively."
"Because aggressive action would draw attention," Silas said. "A retired professor dies of a heart attack in his nursing home room? Unremarkable. Two deaths in the same week? That invites questions. They are buying time."
"Time for what?"
Before Silas could answer, his door opened without a knock. A man in a dark suit entered, followed by Dr. Cordova. The man was tall, fiftyish, with silver hair swept back from a high forehead and eyes the color of slate. He carried a leather briefcase and wore the confident, faintly amused expression of someone accustomed to deference.
"Professor Crane," he said, extending a hand that Silas did not take. "My name is Marcus Voss. I believe you have been asking questions about my company."
The silence that followed was dense, electric. Lila stood slowly from her chair, her weight shifting onto her good leg, her hands loose at her sides. She said nothing, but her presence seemed to fill the room. Voss glanced at her, registered her posture, and smiled.
"Former Special Agent Vance. A pleasure. Your reputation precedes you."
"Yours doesn't," Lila said. "Until yesterday, I'd never heard of you."
"OmniCure is a private company. We prefer to let our results speak for themselves." Voss set his briefcase on Silas's desk and opened it, removing a thin folder. "I came here personally because I believe in direct communication. Professor Crane, your questions about the Aegis-7 trial have reached my office. I understand your concerns. The death of Mr. Finch was tragic. The death of any patient is tragic. But your implication that VitalSync is somehow responsible is not only incorrect—it is dangerous."
"Dangerous to whom?" Silas asked.
"To the thousands of elderly patients who depend on our technology for early detection of life-threatening events. VitalSync has reduced cardiac mortality by twenty-three percent across our trial sites. It is, by every objective measure, a life-saving innovation. Your amateur investigation threatens to undermine public confidence in a system that is demonstrably effective."
Silas opened his blue notebook and read aloud: "Five deaths in this facility over twelve weeks. All trial participants. All classified as low-risk within forty-eight hours of expiration. That is a mortality rate of thirteen and a half percent among a cohort that the algorithm itself deemed safe. If VitalSync is so accurate, how do you explain the discrepancy?"
Voss did not blink. "Statistical clustering. Geriatric populations exhibit clustering of adverse events. It is a well-documented phenomenon. The fact that your five cases occurred in one facility is unfortunate but not statistically significant when viewed against the full trial population of twenty-four hundred patients."
"And the other facilities?" Lila asked, speaking for the first time. "The ones in Albion? The ones we haven't investigated yet? Do they show the same clustering?"
Something flickered in Voss's eyes—a micro-expression that Silas catalogued as recognition-then-suppression. "The trial data is confidential under FDA regulations. I cannot share site-specific results. But I can assure you that OmniCure complies fully with all regulatory requirements. We have nothing to hide."
"Then you won't mind if we continue asking questions," Lila said.
Voss closed his briefcase with a sharp click. "I cannot prevent you from asking questions. But I should warn you that OmniCure's intellectual property is protected by some of the most robust trade-secret laws in Meridian jurisprudence. Any attempt to access, reverse-engineer, or publicly disclose the VitalSync algorithm without authorization would constitute a federal crime under the Economic Espionage Act. The penalties are severe." He looked at Silas. "Prison is not kind to elderly men."
"Is that a threat?" Silas asked.
"It is a clarification. I want there to be no misunderstanding between us." Voss withdrew a second business card from his breast pocket and placed it on the desk beside the first. "If you have further concerns, my legal department is available to address them through formal channels. I trust you will use them."
He left without shaking hands. Dr. Cordova followed him out, her tablet clutched to her chest like a shield. The door closed with a soft, pneumatic hiss.
Lila waited until their footsteps faded. "He's scared."
"Or he is very good at pretending to be reasonable while issuing threats. I am inclined toward the latter interpretation."
"Both can be true. The question is what he's scared of. If OmniCure is as clean as he claims, he'd ignore us. Instead, the CEO flies two hundred miles for a personal visit at dawn. That's not confidence. That's damage control."
Silas sat on the edge of his bed, his exhaustion momentarily forgotten. "He mentioned other facilities in Albion. You noticed his reaction. There is something there."
"Albion is outside Meridian jurisdiction. The FBI can't investigate there without a bilateral agreement, and those take months. If OmniCure is hiding something, Albion is where they'd hide it."
"Then we need someone in Albion."
Lila was quiet for a moment. Then she said: "I know a person. Retired journalist. She used to cover pharmaceutical corruption for the Albion Times before the paper was bought out. Her name is Cora Delaney. She's old, she's cranky, and she owes me a favor from twenty years ago. If there's a story in Albion, she'll find it."
That afternoon, Lila placed another call from the library payphone. The conversation lasted thirty minutes. When she returned to the table where Silas was reviewing obituary records, her expression was grim.
"Cora will help. She's already heard rumors. A nursing home in the Albion city of Dunmara had three sudden deaths last month, all in an OmniCure trial. The local coroner ruled them natural. The families accepted the rulings. But a nurse at the facility filed an anonymous complaint with the Albion Health Authority, claiming the VitalSync terminals displayed error codes immediately after each death. The complaint was dismissed for lack of evidence."
"Error codes," Silas repeated. "Specific codes?"
"The nurse didn't record them. She was too scared. Cora is going to interview her, but it will take time. The nurse has gone into hiding."
Silas closed his eyes and let the information settle into the logical framework he was constructing. Error codes. False positives. Deaths clustered around trial sites. A CEO who flies across the country to silence questions. The pieces were assembling themselves into a shape he did not yet want to name.
"I need to examine the algorithm," he said. "Not the user interface. The core logic. The training data. The decision trees. Without that, we have only correlations, not proof."
"How do you propose to do that? Voss just threatened you with federal prison."
"Voss is protecting his trade secrets. But trade secrets are not absolute. There are exceptions for whistleblowers, for public health emergencies, for evidence of criminal activity. If we can demonstrate probable cause that VitalSync is being used to commit murder, a court could compel OmniCure to disclose the algorithm."
"That's a big if. And it requires a judge who understands what an algorithm is. Most of the federal judiciary still thinks encryption is a type of wallpaper."
Silas opened his notebook to a fresh page. "Then we need to find a judge who doesn't. Or we need to find someone inside OmniCure who is willing to talk."
That night, Silas sat in the common room, watching the evening news on the wall-mounted television. Senator Eleanor Cross was speaking again, this time on the floor of the Meridian Senate, her voice amplified by the chamber's acoustics. "The Algorithmic Governance Act is not about stifling innovation. It is about ensuring that innovation serves humanity rather than replacing it. A machine that makes life-and-death decisions without transparency, without accountability, without human oversight, is not a tool. It is a tyrant."
The camera cut to the Senate majority leader, a heavyset man from the Southern Prefectures, who dismissed the bill as "anti-business hysteria." The segment ended. A commercial for OmniCure followed: soothing images of elderly people gardening, playing with grandchildren, smiling at nurses. A voiceover intoned: "VitalSync. Because every heartbeat matters."
Silas turned off the television and walked back to Room 104. On his desk, next to the two business cards, lay a plain white envelope that had not been there before. His name was written on the front in handwriting that was small, precise, and unfamiliar. He opened it carefully, using a letter opener from his desk drawer.
Inside was a single sheet of paper, folded once. On it, in the same handwriting, was a message:
*The termination index is real. It is activated remotely. The predictions are not predictions. They are commands. I know because I wrote the code. If you want proof, look at the data logs for patient AG7-2237 on the night of December 11. I can help you, but not here. The Company watches everything. Burn this note. I will find you.*
There was no signature. Only a string of numbers at the bottom: *47.238.91.4*—an IP address.
Silas read the note three times. Then he held it over the metal wastebasket, lit a match, and watched it burn. The ashes curled into gray petals and settled among the crumpled papers.
He sat in the vinyl armchair, the one Lila had occupied that morning, and stared at the space where the envelope had lain. Someone inside OmniCure had reached out to him. Someone who knew the code, who understood the deception, who was either courageous enough to expose it or terrified enough to seek protection.
The termination index.
The phrase echoed in his mind, connecting to the diagram he had drawn days earlier: the red arrows pointing from VitalSync to a question mark. He had written *What if they are instructions?* Now he had his answer. The algorithm was not predicting death. It was issuing orders. And somewhere, in the silent servers of OmniCure Biotech, a program was executing those orders, selecting patients, determining timelines, manufacturing outcomes.
The perfect crime, he realized, was not the murder itself. It was the architecture of plausible deniability that surrounded it. No human hand pulled the trigger. No poison was administered. No pillow was pressed to a face. Only a stream of data, a fluctuation of insulin, a shift in electrolyte balance—all automated, all documented as natural progression, all invisible to the forensic tools of a previous century.
He picked up the business card that Marcus Voss had left and studied the silver helix logo. Then he turned it over. On the back, in the same silver ink, was a motto he had not noticed before: *Salus Per Algorithmum.* Health Through Algorithm.
Beneath it, in smaller type, a copyright date: *2024.*
He placed the card in his notebook and closed it. Outside, the parking lot lights flickered twice, then steadied. The fluorescent hum continued. The machine continued to run.
And somewhere in the darkness of Room 309, Eleanor Vance slept on, unaware that she had been granted a reprieve—or that reprieves, like predictions, could be revoked.
No comments yet. Be the first to comment!